StreetInsider.com News Articles

Form 8-K CEL SCI CORP For: Jun 14

Tue, 16 Jun 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260616/26655118.html

Form 8-K CEL SCI CORP For: Jun 14

Tue, 16 Jun 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260616/26655118.html

CEL-SCI closes $2.5M stock offering at $1.00 per share

Tue, 16 Jun 2026 16:01:38 -0400

CEL-SCI Corporation (NYSE American: CVM) has closed a best-efforts offering of 2,500,000 shares of common stock at $1.00 per share, raising approximately $2.5 million in gross proceeds before placement agent fees and other expenses, according to a press release from the company.

ThinkEquity served as the sole placement agent for the offering. The securities were offered under a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on July 3, 2025, which was declared effective on August 12, 2025.

CEL-SCI said it intends to use the net proceeds to fund continued development of its investigational therapy Multikine,

CEL-SCI Announces Closing of Offering

Tue, 16 Jun 2026 16:01:00 -0400

VIENNA, Va.--(BUSINESS WIRE)--

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $1.00 per share. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $2.5 million.

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.

ThinkEquity acted as the

CEL-SCI Announces Closing of Offering

Tue, 16 Jun 2026 16:01:00 -0400

VIENNA, Va.--(BUSINESS WIRE)--

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.

ThinkEquity acted as the

CEL-SCI Announces Closing of Offering

Tue, 16 Jun 2026 16:01:00 -0400

VIENNA, Va.--(BUSINESS WIRE)--

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.

ThinkEquity acted as the

CEL-SCI Announces Closing of Offering

Tue, 16 Jun 2026 16:01:00 -0400

VIENNA, Va.--(BUSINESS WIRE)--

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.

ThinkEquity acted as the

CEL-SCI Announces Closing of Offering

Tue, 16 Jun 2026 16:01:00 -0400

VIENNA, Va.--(BUSINESS WIRE)--

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.

ThinkEquity acted as the

CEL-SCI Announces Closing of Offering

Tue, 16 Jun 2026 16:01:00 -0400

VIENNA, Va.--(BUSINESS WIRE)--

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.

ThinkEquity acted as the

CEL-SCI Announces Closing of Offering

Tue, 16 Jun 2026 16:01:00 -0400

VIENNA, Va.--(BUSINESS WIRE)--

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.

ThinkEquity acted as the

CEL-SCI Announces Closing of Offering

Tue, 16 Jun 2026 16:01:00 -0400

VIENNA, Va.--(BUSINESS WIRE)--

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.

ThinkEquity acted as the

CEL-SCI plans U.S. study and Saudi deal for head and neck drug

Tue, 16 Jun 2026 08:02:07 -0400

CEL-SCI Corporation (NYSE American: CVM) outlined plans to advance its investigational cancer immunotherapy Multikine through a U.S. confirmatory registration study and a commercial partnership in Saudi Arabia, according to a company press release.

The confirmatory registration study, expected to begin in summer 2026, will enroll 212 newly diagnosed patients with locally advanced resectable head and neck cancer who have low PD-L1 tumor expression and no lymph node involvement. The study is designed to demonstrate improvement in overall survival and support a potential U.S. regulatory submission. Multikine has not been approved by the FDA, and its safety and efficacy have not been

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

Tue, 16 Jun 2026 08:00:00 -0400

U.S. Confirmatory Registration Study expected to begin Summer 2026

Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target patient population and improved quality of life